Fulcrum Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Fulcrum Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.28K	Buy	+70	New	+$3.36K	﹤0.01%	809

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Fulcrum Asset Management's SUPN Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 70 shares worth $3.28K. The stake represents ﹤0.01% of the portfolio and ranks #809 among its holdings.

332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Fulcrum Asset Management held 70 shares of Supernus Pharmaceuticals worth $3.28K as of Q2 2026.
Supernus Pharmaceuticals was a new Fulcrum Asset Management position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #809 holding.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.